| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Allergen-specific immunotherapy is an effective treatment for allergic rhinitis. The most common administration route is subcutaneous, which may necessitate more than 50 allergen injections during 3 to 5 years.In an open pilot investigation followed by a double-blind, placebo-controlled study, patients with allergic rhinitis were treated with 3 intralymphatic inguinal injections of Cry j1 or placebo.At visit 2 to 4, the study subjects received three 0.1 ml injections with either placebo or 20 JAU of a standardized Japanese pollen extracts.
Clinical pre and post treatment outcomes and the activation pattern of peripheral antibodies were assessed. Intralymphatic immunotherapy (ILIT) with Cry j1 did not elicit any severe adverse events. Patients receiving active treatment displayed an initial increase in allergen-specific IgE and IgG level. A clinical improvement was seen in active treatment group, but not in the placebo group.
|
